DEA
| HOME | PRIVACY POLICY | CONTACT US | SITE DIRECTORY |
Skip Navigation

Global News Local News

 News from DEA
   News Releases
   Speeches & Testimony
   Photo Library
   Audio/Video Library
   FOIA

 Briefs & Background
 Drug Trafficking & Abuse
   Drug Information
   Prescription Drug Info.
   Drug Trafficking
   State Factsheets
 Law Enforcement
   Recent Cases
   Major Operations
   Intelligence Reports
   DEA Fugitives
   Training Opportunities
   Statistics
 Drug Policy
   Controlled Substances Act
   Federal Trafficking Penalties
   Drug Scheduling
 DEA Resources
   For Contractors
   For Job Applicants
   For Law Enforcement
   For Legislators
   For Parents & Teachers
   For Physicians/Registrants
   For Students
   For Victims of Crime

 Inside the DEA
   DEA's Mission
   DEA Leadership
   Programs & Operations
   Publications Library
   DEA Museum
   Staffing & Budget
   Office Locations
   DEA History
   DEA Wall of Honor
   Office of Diversion
   Acquisitions & Contracts
   DOJ Homepage


[print friendly page]

Anorectic Drugs

A number of drugs have been developed and marketed to replace amphetamines as appetite suppressants. These anorectic drugs include benzphetamine (Didrex®), diethylproprion (Tenuate®, Tepanil®), mazindol (Sanorex®, Mazanor®), phendimetrazine (Bontril®, Prelu-27®), and phentermine (lonamin®, Fastin®, Adipex®). These substances are in Schedule III or IV of the CSA and produce some amphetamine-like effects. Of these diet pills, phentermine is the most widely prescribed and most frequently encountered on the illicit market. Two Schedule IV anorectics often used in combination with phentermine (phen-fen combo), fenfluramine and dexfenfluramine, were removed from the U.S. market due to heart valve problems.

 
www.dea.gov